Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction of Biktarvy and Feminizing Hormones in Trans Women with HIV
NCT05663892Phase 4Active, not recruiting
- Sponsor
- Maple Leaf Research
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Maple Leaf Research. Primary endpoints: Minimum plasma concentrations of BIC, FTC, and TAF at 2 months, Maximum plasma concentrations of BIC, FTC, and TAF at 2 months and 6 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05663892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663892.